Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Oscillating Pulsed Electric Fields Strike Major Blow to Resistant Bacteria and Cancer

By BiotechDaily International staff writers
Posted on 29 Oct 2013
Image: Time lapse photos of three leukemia cells being treated with OPEF. Two of the three cells are literally shattered by the treatment (Photo courtesy of PRNewsFoto/Novobiotronics Inc.).
Image: Time lapse photos of three leukemia cells being treated with OPEF. Two of the three cells are literally shattered by the treatment (Photo courtesy of PRNewsFoto/Novobiotronics Inc.).
Oscillating pulsed electric field (OPEF) technology is delivering a one-two punch against cancer and antibiotic-resistant bacteria using a pulsed electronic signal that destroys cancer cells and disables antibiotic resistance in deadly methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas bacteria.

Novobiotronics (Saratoga Springs, NY, USA), a world leader in research on the biologic effects of OPEFs as a future nontoxic medical treatment, was the first company to confirm the capability of OPEFs to destroy 30%–60% of leukemia cells. In laboratory research, OPEF also demonstrated an ability to slow cancer growth by up to 60%. OPEF has also shown an ability to disarm antibiotic resistance in the lethal bacteria MRSA, rendering it susceptible to typically available antibiotics as well as inhibiting its growth.

Novobiotronics Inc., a nonprofit educational and scientific research, has report a significant breakthrough in the battle against cancer and harmful antibiotic-resistant strains of bacteria including the “superbug” deadliness of MRSA, and Pseudomonas aeruginosa (PS).

Anthony Holland, president of Novobiotronics, reported the findings of recent laboratory research done in collaboration with the State University of New York (Stony Brook, USA) that their new electronic treatment of antibiotic resistant MRSA and PS has both a bacteriostatic effect as well as a bactericidal effect when used in combination with tiny amounts of conventional antibiotics to which the deadly organisms are otherwise normally resistant.

The current standard medical treatment of antibiotic-resistant bacterial infections utilizes combinations of different types of antibiotics, but those combinations can result in very serious and even dangerous side effects. Physicians even induce some patients into a coma to reduce the severity of the drug side effects.

Novobiotronics’ new technology involves the use of a “plasma antenna,” a type of a helium gas filled fluorescent light used to broadcast oscillating pulsed electric fields at cancer cells and bacteria. These OPEFs can kill cancer cells, slow the growth rate of the cancer cells and bacteria greatly, and actually quash the bacteria’s ability to resist antibiotics. When used in combination with very small amounts of a traditional antibiotic, OPEF has demonstrated an ability to destroy MRSA and PS bacteria.

Novobiotronics’ collaborators from the State University of New York presented their joint findings at a September 2013 meeting of the American Society for Microbiology, held in Denver (CO, USA).

Related Links:

State University of New York


Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.